Phase 1Completed
A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )
- Sponsor
- Genuine Research Center, Egypt (Industry)
- Enrollment
- 27 enrolled
- Conditions
- Healthy
- Interventions
- Glibesyn; Daonil
- Ages
- adults
- Registry
- NCT03855306
Full record on ClinicalTrials.gov
From the registry
Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Glibenclamide from Glibesyn 5 mg tablets (Manufactured by Medochemie LTD Cyprus) and Daonil 5 mg tablets (Sanofi-Aventis Cyprus Ltd. ) after a single oral dose administration of each to healthy adults under fasting conditions
Primary outcomes
- Maximal measured plasma concentration (Cmax)
History
Registered
Study completion
Primary completion
Started